As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Societies around the world are facing the paradoxal epidemic development of prostate cancer (PCa) as a non-communicable disease. PCa is the most frequently diagnosed cancer for men in several countries such as the USA. Permanently improving diagnostics and treatments in the PCa management causes an impressive divergence between, on one hand, permanently increasing numbers of diagnosed PCa cases and, on the other hand, stable or even slightly decreasing mortality rates. 

The article summarises knowledge accumulated in regard to the PCa-relevant non-modifiable and modifiable risk factors, highlights current deficits in PCa managements and presents innovative solutions in the context of predictive, preventive and personalised (3P) medicine.

SCImago Journal Rank (SJR) measures weighted citations received by the journal. In 2019, the SJR for EPMA Journal is 1.263, placing it in the 1^st quartile of the 'Health Policy' category, with particularly high level of international collaboration amongst researchers.

Scopus CiteSore measures average citations received per document published. The 2019 CiteSore for EPMA Journal is 7.700. This ranks the journal as 8^th in the 'Health Policy' category, within the 96^th percentile.

Source-Normalized Impact per Paper (SNIP) measures actual citations received relative to citations expected for the journal’s subject field. The 2019 SNIP for EPMA Journal is 1.469.

Dr. Golubnitschaja is the head of the world's first Predictive, Preventive and Personalised (3P) Medicine unit at the Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.